Management of breast cancer in the older woman

Cancer Control

Volumn 8, Issue 5, 2001, Pages 431-441

  Balducci, Lodovico ^a   Extermann, Martine ^a   Carreca, Ignazio ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIESTROGEN; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FULVESTRANT; GEMCITABINE; MELPHALAN; METHOTREXATE; NAVELBINE; PREDNISONE; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; VINCRISTINE;

AGE; AGED; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BONE MARROW TOXICITY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; EARLY DIAGNOSIS; ELDERLY CARE; FEMALE; HORMONE RECEPTOR INTERACTION; HUMAN; LIFE EXPECTANCY; LYMPHADENECTOMY; MASTECTOMY; ONCOGENE NEU; PATIENT SATISFACTION; POSTOPERATIVE COMPLICATION; RECURRENCE RISK; REMISSION; SURGICAL ANATOMY; TREATMENT CONTRAINDICATION;

EID: 0034805022     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480100800507     Document Type: Article

References (69)

1. Breast cancer and aging: Clinical interactions
2. Aging and cancer in America: Demographic and epidemiologic perspectives
3. Physiology of aging: Relevance to symptom perceptions and treatment tolerance
4. Cancer and aging: An evolving panorama
5. The value of the comprehensive geriatric assessment in the management of the older cancer patient
6. A practical approach to the older cancer patient
7. General guidelines for the management of older patients with cancer
8. Toward an understanding of frailty
9. Comorbidity and functional status are independent in older cancer patients
10. A simple procedure for general screening for functional disability in elderly patients
11. Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance
12. Antineoplastic chemotherapy of the older cancer patient
13. Cancer chemotherapy in the older patients
14. Patients aged ≥70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy
15. Hematopoietic growth factors in the older cancer patient
16. Cancer in the frail patient: A coming epidemic
17. Breast conservation is the treatment of choice in small breast cancer: Long term-results of a randomized trial
18. Postmastectomy radiotherapy
19. Factors affecting recurrence in lumpectomy without irradiation for breast cancer
20. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer
21. Clinical course of cancer in the elderly
22. The change in tumor aggressiveness with age: Lessons from experimental animals
23. Relationship of patients age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer
24. Why are local recurrences after breast-conserving therapy more frequent in younger patients?
25. Breast irradiation in the older woman: A toxicity study
26. Conservative surgery and radiotherapy
27. Local control following breast-conserving surgery for invasive cancer: Results of clinical trials
28. The role of radiotherapy and tamoxifen in the management of node-negative breast cancer -1.0 cm treated with lumpectomy: Preliminary results of NSABP protocol B-21
29. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection
30. Outpatient treatment of clinically node-negative breast cancer in elderly women
31. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials
32. Breast cancer sentinel node metastases: Histopathologic detection and clinical significance
33. Breast cancer in the elderly: Surgery improves survival. The results of a cancer research campaign trial
34. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer. The G.R.E.T.A. trial
35. Tamoxifen for early breast cancer: An overview of the randomised trials
36. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
37. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer
38. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer
39. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer: Finnish Breast Cancer Group
40. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: A brief overview
41. Polychemotherapy for early breast cancer: An overview of the randomised trials
42. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up
43. Evolving concepts in the systemic adjuvant treatment of breast cancer
44. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience
45. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer
46. Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer
47. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience
48. Dose and dose intensity of adjuvant chemotherapy for stage II node-positive breast carcinoma
49. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen. Results from the National Surgical Breast and Bowel Project B-16
50. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multicentric Italian study
51. Randomized 2×2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: German Breast Cancer Study Group
52. Adjuvant therapy of breast cancer: A Southwest Oncology Group experience
53. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for post-menopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group Study
54. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results
55. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer
56. CMF added to tamoxifen as adjuvant therapy in post-menopausal women with node positive estrogen and/or progesterone receptor-positive breast cancer: Negative results of a randomized clinical trial
57. Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group trial VII
58. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group
59. Benefits of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors. 5-Year follow-up results of French Adjuvant Study Group 05 randomized trial
60. Tamoxifen (T) versus cyclophosphamide, Adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: A Southwest Oncology Group Phase III Intergroup Trial (SWOG-8814, INT-0100)
61. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors
62. Adjuvant therapy for node-negative breast cancer: An update of NSABP findings
63. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer
64. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
65. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer
66. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen (T) alone
67. What threshold for adjuvant therapy in older breast cancer patients?
68. Management of the frail person with advanced cancer
69. Symptomatic management of the older person with cancer